{
    "organizations": [],
    "uuid": "1ac1de774842013fa4e2df94fa45a520ce93581d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-inflarx-receives-ind-acceptance-to/brief-inflarx-receives-ind-acceptance-to-proceed-with-a-phase-iib-trial-with-lead-candidate-ifx-1-in-hidradenitis-suppurativa-idUSASM000HY2",
    "ord_in_thread": 0,
    "title": "BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "#Market News January 9, 2018 / 3:42 PM / Updated 25 minutes ago BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa Reuters Staff 1 Min Read \nJan 9 (Reuters) - Inflarx Nv: \n* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA \n* INFLARX NV - ‍INTENDS TO INITIATE THE STUDY ON IFX-1 IN Q1 OF 2018​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-09T17:42:00.000+02:00",
    "crawled": "2018-01-09T17:56:03.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "ind",
        "acceptance",
        "proceed",
        "phase",
        "iib",
        "trial",
        "lead",
        "candidate",
        "hidradenitis",
        "suppurativa",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "inflarx",
        "nv",
        "inflarx",
        "receives",
        "ind",
        "acceptance",
        "proceed",
        "phase",
        "iib",
        "trial",
        "lead",
        "candidate",
        "hidradenitis",
        "suppurativa",
        "inflarx",
        "nv",
        "initiate",
        "study",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}